Lv1
30 积分 2024-05-25 加入
只要我拥有，只要你需要，必相助
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
7天前
已完结
Mutation landscape of TSC1/TSC2 in Chinese patients with tuberous sclerosis complex
1个月前
已完结
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
1个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)
1个月前
已完结
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
1个月前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
1个月前
已完结
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial
2个月前
已完结
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
3个月前
已完结
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
4个月前
已完结
皖公网安备34019202002308
